Citigroup’s Cytokinetics CYTK Stock Holding History

Citigroup’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.19M	Buy	+18,000	New	+$1.37M	﹤0.01%	3201
2026 Q1	–	Sell	-60,000	Closed	-$3.81M	–	6031
2025 Q4	$3.81M	Buy	60,000 +35,000	+140%	+$2.18M	﹤0.01%	2215
2025 Q3	$1.37M	Sell	25,000 -5,000	-17%	-$206K	﹤0.01%	2959
2025 Q2	$991K	Sell	30,000 -65,500	-69%	-$2.28M	﹤0.01%	3201
2025 Q1	$3.84M	Sell	95,500 -1,300	-1%	-$59.7K	﹤0.01%	2152
2024 Q4	$4.55M	Sell	96,800 -700	-0.7%	-$36.4K	﹤0.01%	2060
2024 Q3	$5.15M	Buy	+97,500	New	+$5.43M	﹤0.01%	1820
2024 Q1	–	Sell	-30,000	Closed	-$2.5M	–	5676
2023 Q4	$2.5M	Buy	+30,000	New	+$1.09M	﹤0.01%	2053
2023 Q3	–	Sell	-55,000	Closed	-$1.79M	–	5692
2023 Q2	$1.79M	Sell	55,000 -29,400	-35%	-$1.09M	﹤0.01%	2316
2023 Q1	$2.97M	Buy	84,400 +54,400	+181%	+$2.22M	﹤0.01%	1767
2022 Q4	$1.37M	Buy	+30,000	New	+$1.29M	﹤0.01%	2336
2022 Q3	–	Sell	-20,000	Closed	-$786K	–	5917
2022 Q2	$786K	Buy	+20,000	New	+$805K	﹤0.01%	2871

Other funds holding CYTK

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return

Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.9B AUM 30.31% 1-Year Est. Return

Citigroup's CYTK Position: Q3 2026 in Review

Citigroup reduced its Cytokinetics (CYTK) stake by 74% in Q3 2026, selling an estimated $18.2M and leaving 84,191 shares worth $5.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2038.

Citigroup first reported a position in CYTK in Q2 2013 and has held it in 54 quarters since. The position peaked at $27.5M in Q2 2026. 147 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

Citigroup held 84,191 shares of Cytokinetics worth $5.55M as of Q3 2026.
Citigroup sold 238,741 Cytokinetics shares in Q3 2026, an estimated $18.2M.
Cytokinetics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2038 holding.
Citigroup first reported a position in Cytokinetics in Q2 2013 and has held it in 54 quarters since.
Citigroup's Cytokinetics position peaked at $27.5M in Q2 2026.
147 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.